The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
作者： Giorgio Scagliotti , Nasser Hanna , Frank Fossella , Katherine Sugarman , Johannes Blatter
DOI: 10.1634/THEONCOLOGIST.2008-0232
关键词:
摘要: Background. Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. Methods. One study tested pemetrexed versus docetaxel in previously treated patients (n= 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n= 1,725) with advanced NSCLC. Cox proportional hazard models were used to …
alphamedpress.org
oup.com参考文章(44)
L. G. Mendelsohn, S. B. Gates, L. L. Habeck, V. J. Chen, K. A. Shackelford, Chuan Shih, Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Seminars in Oncology. ,vol. 26, pp. 42- 47 ,(1999)
Roberts Ef, Dempsey Ja, Bewley, Chen Vj, Schultz Rm, Shih C, Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Seminars in Oncology. ,vol. 26, pp. 68- 73 ,(1999)
E A Rayl, K A Shackelford, L L Habeck, V F Patel, L G Mendelsohn, V J Chen, S B Gates, R M Schultz, M Ratnam, J R Bewley, S L Andis, W C MacKellar, D J Soose, B A Moroson, W Kohler, L S Gossett, G P Beardsley, C Shih, LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes Cancer Research. ,vol. 57, pp. 1116- 1123 ,(1997)
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
F. L. Pimentel, J. von Pawel, R. G. Martins, S. Novello, J. Douillard, M. O’Brien, A. M. Liepa, L. Simms, Resource utilization by non-small cell lung cancer histology: Results from the randomized, phase III trial of pemetrexed/cisplatin versus gemcitabine/cisplatin Journal of Clinical Oncology. ,vol. 26, pp. 8097- 8097 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.8097
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Shrikanta Chattopadhyay, Rongbao Zhao, Eugenia Tsai, Vern L. Schramm, I. David Goldman, The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity. Molecular Cancer Therapeutics. ,vol. 5, pp. 2549- 2555 ,(2006) , 10.1158/1535-7163.MCT-06-0313
William Pao, Vincent A. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions Journal of Clinical Oncology. ,vol. 23, pp. 2556- 2568 ,(2005) , 10.1200/JCO.2005.07.799
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Bjørn H Grønberg, Roy M Bremnes, Ulf Aasebø, Paal Brunsvig, Øystein Fløtten, Tore Amundsen, Christian von Plessen, Mari Wang, Stein Sundstrøm, Norwegian Lung Cancer Study Group, A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer Lung Cancer. ,vol. 63, pp. 88- 93 ,(2009) , 10.1016/J.LUNGCAN.2008.04.003